Amy Beth Vanduyn Sells 604 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 604 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $26.98, for a total transaction of $16,295.92. Following the completion of the transaction, the senior vice president now directly owns 115,029 shares of the company’s stock, valued at approximately $3,103,482.42. This represents a 0.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Amy Beth Vanduyn also recently made the following trade(s):

• On Monday, January 6th, Amy Beth Vanduyn sold 1,311 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total transaction of $34,885.71.
• On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The shares were sold at an average price of $20.93, for a total value of $532,605.71.

Phreesia Stock Performance

Phreesia stock opened at $27.24 on Monday. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.58 billion, a P/E ratio of -18.53 and a beta of 0.94. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.16. The firm has a 50-day moving average of $23.54 and a 200-day moving average of $22.83.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. During the same quarter last year, the business posted ($0.58) EPS. The business’s revenue was up 16.6% on a year-over-year basis. Sell-side analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC increased its position in shares of Phreesia by 2,179.7% during the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after buying an additional 1,395 shares during the period. Lombard Odier Asset Management USA Corp bought a new stake in Phreesia during the 2nd quarter valued at approximately $202,000. Point72 DIFC Ltd purchased a new position in shares of Phreesia during the 2nd quarter worth approximately $209,000. XTX Topco Ltd bought a new position in shares of Phreesia in the 3rd quarter worth approximately $247,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Phreesia in the 2nd quarter valued at approximately $301,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Truist Financial upped their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Friday, January 10th. KeyCorp upped their price objective on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Finally, Citigroup lifted their target price on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia presently has a consensus rating of “Buy” and an average target price of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.